Use of the prodrug acid ethyl ester of N - (3-methoxy-3-oxopropyl 3-carboxy - 1 -) - (4S) - P - fenilfenilmetil) - 4 - amino - (2R) - metilbutanoico or acid n - (3-methoxy-3-oxopropyl 3-carboxy - 1 -) - (4S) - P - (2R) - fenilfenilmetil) - 4 - amino - metilbutanoico, inhibitors of NEP with Valsartan in treating Heart Failure with pool Ion preserved ejection.
The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof； or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling； a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling.USO DEL ÉSTER DE ETILO DEL ÁCIDO N-(3-CARBOXI-1-OXOPROPIL)-(4S)-p-FENILFENILMETIL-4-AMINO-(2R)-METILBUTANOICO CON VALSARTAN (LCZ696) PARA EL TRATAMIENTO, PREVENCIÓN O RETRASO DE LA PROGRESIÓN DE UNA ENFERMEDAD CARACTERIZADA POR EL ENSANCHAMIENTO Y/O REMODELADO AURICULAR EN EL QUE LA ENFERMEDAD ES INSUFICIENCIA CARDIACA.
